

Pheochromocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/P779426F5983EN.html>

Date: August 2022

Pages: 50

Price: US\$ 2,000.00 (Single User License)

ID: P779426F5983EN

Abstracts

Pheochromocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pheochromocytoma - Drugs In Development, 2022, provides an overview of the Pheochromocytoma (Oncology) pipeline landscape.

Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops in cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath and constipation. Risk factors include multiple endocrine neoplasia type II (MEN), Von Hippel-Lindau disease (VHL) and neurofibromatosis 1 (NF1).

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pheochromocytoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Pheochromocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pheochromocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pheochromocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 10, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pheochromocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Pheochromocytoma (Oncology).

The pipeline guide reviews pipeline therapeutics for Pheochromocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Pheochromocytoma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Pheochromocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Pheochromocytoma (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Pheochromocytoma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Pheochromocytoma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Pheochromocytoma - Overview
- Pheochromocytoma - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Pheochromocytoma - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Pheochromocytoma - Companies Involved in Therapeutics Development
- Advanced Accelerator Applications SA
- AstraZeneca Plc
- Chimerix Inc
- Enterome Bioscience SA
- Exelixis Inc
- Gibson Oncology LLC
- Ipsen SA
- Jubilant DraxImage Inc
- Lixte Biotechnology Holdings Inc
- Merck & Co Inc
- Pfizer Inc
- Tarveda Therapeutics Inc
- Vyriad Inc
- Pheochromocytoma - Drug Profiles
- 211At-MABG - Drug Profile
- Product Description
- Mechanism Of Action
- belzutifan - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- cabozantinib s-malate - Drug Profile

Product Description
Mechanism Of Action
History of Events
EO-2401 - Drug Profile
Product Description
Mechanism Of Action
History of Events
iobenguane I 131 - Drug Profile
Product Description
Mechanism Of Action
History of Events
lanreotide acetate PR - Drug Profile
Product Description
Mechanism Of Action
History of Events
LB-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LMP-400 - Drug Profile
Product Description
Mechanism Of Action
History of Events
lutetium Lu 177 dotatate - Drug Profile
Product Description
Mechanism Of Action
History of Events
olaparib - Drug Profile
Product Description
Mechanism Of Action
History of Events
ONC-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PEN-221 - Drug Profile
Product Description
Mechanism Of Action
History of Events

sunitinib malate - Drug Profile

Product Description

Mechanism Of Action

History of Events

Voyager-V1 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Pheochromocytoma - Dormant Projects

Pheochromocytoma - Product Development Milestones

Featured News & Press Releases

Jul 27, 2021: Clinical trial of Belzutifan in pancreatic NETs and Pheo/Para

May 28, 2020: Oncoceutics to present additional data at ASCO showing clinical benefit from ONC201 for Cancer Patients

Jan 09, 2017: Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA

Comments on Lutathera NDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Pheochromocytoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pheochromocytoma - Pipeline by Advanced Accelerator Applications SA, 2022
Pheochromocytoma - Pipeline by AstraZeneca Plc, 2022
Pheochromocytoma - Pipeline by Chimerix Inc, 2022
Pheochromocytoma - Pipeline by Enterome Bioscience SA, 2022
Pheochromocytoma - Pipeline by Exelixis Inc, 2022
Pheochromocytoma - Pipeline by Gibson Oncology LLC, 2022
Pheochromocytoma - Pipeline by Ipsen SA, 2022
Pheochromocytoma - Pipeline by Jubilant DraxImage Inc, 2022
Pheochromocytoma - Pipeline by Lixte Biotechnology Holdings Inc, 2022
Pheochromocytoma - Pipeline by Merck & Co Inc, 2022
Pheochromocytoma - Pipeline by Pfizer Inc, 2022
Pheochromocytoma - Pipeline by Tarveda Therapeutics Inc, 2022
Pheochromocytoma - Pipeline by Vyriad Inc, 2022
Pheochromocytoma - Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Pheochromocytoma, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Pheochromocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/P779426F5983EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P779426F5983EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

